Results 161 to 170 of about 1,466,333 (379)

Fc receptors for IgG (Fc gamma Rs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the Fc gamma R. [PDF]

, 1991
Ruth I. Connor, N B Dinces, Alexandra L. Howell, J.L. Romet-Lemonne, J.‐L. Pasquali, Michael W. Fanger   +5 more
openalex   +1 more source

Patient‐derived xenograft models in pan‐cancer: From bench to clinic

Interdisciplinary Medicine, EarlyView.
Abstract Patient‐derived xenograft (PDX) models provide a robust preclinical platform that preserves the genetic and phenotypic heterogeneity of patient tumors while mirroring their tumor genetic characteristics, which retain malignant cells and the tumor pathological structure, making them valuable for studying tumor progression and developing ...
Jiatong Li, Ao Gu, Nannan Tang, Gokhan Zengin, Meng‐Yao Li, Yingbin Liu   +5 more
wiley   +1 more source

A mechanistic quantitative systems pharmacology model platform for translational efficacy evaluation and checkpoint combination design of bispecific immuno-modulatory antibodies

Frontiers in Pharmacology
Over the past 2 decades, tumor immunotherapies have witnessed remarkable advancements, especially with the emergence of immune checkpoint-targeting bispecific antibodies.
Yiyang Xu, Siyuan Yang, Qi Rao, Yuan Gao, Guanyue Zhou, Dongmei Zhao, Xinsheng Shi, Yi Chai, Chen Zhao, Chen Zhao   +9 more
doaj   +1 more source

Advanced single‐cell RNA sequencing in tumor immunology

Interdisciplinary Medicine, EarlyView.
This review highlights the applications of advanced single‐cell RNA sequencing (scRNA‐seq) technologies in tumor immunology. It summarizes representative scRNA‐seq methods according to technical principles, with a focus on single‐cell T cell receptor sequencing. This review also discusses how scRNA‐seq is used to construct immune cell atlases of tumors,
Yilong Liu, Xiyuan Yu, Zhipeng Han, Qiuyang Wei, Qi Niu, Chaoyong Yang, Jie P. Li, Zijian Guo, Huimin Zhang   +8 more
wiley   +1 more source

FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy [PDF]

, 1997
Thomas Valerius, Bernhard Stockmeyer, Annemiek B. van Spriel, Robert F. Graziano, Ingrid E. van den Herik–Oudijk, Roland Repp, Yashwant M. Deo, John Lund, Joachim R. Kalden, Martin Gramatzki, Jan G. J. van de Winkel   +10 more
openalex   +1 more source

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, EarlyView.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source

A pivotal decade for bispecific antibodies?

mAbs
Bispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of mAbs and their adoption as therapeutic agents in the 1980s and 1990s, the development of bsAbs has held substantial appeal.
Marlena Surowka, Christian Klein
openaire   +3 more sources

Inhibition of bispecific monoclonal antibody (bsAb)‐targeted cytolysis by human anti‐mouse antibodies in ovarian carcinoma patients treated with bsAb‐targeted activated T‐lymphocytes [PDF]

, 1995
C. B. H. W. Lamers, Jan W. Gratama, Sven O. Warnaar, G. Stoter, R. L. H. Bolhuis   +4 more
openalex   +1 more source

Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum

Pediatric Blood &Cancer, EarlyView.
ABSTRACT High‐risk neuroblastoma is a poor prognosis cancer of the sympathetic nervous system that accounts for a disproportionate number of childhood cancer deaths. Many viable biological targets have been identified, and the number of potential combinations is even larger.
Steven G. DuBois, Lucas Moreno, John Anderson, Shahab Asgharzadeh, Ro Bagatell, Maja Beck‐Popovic, Jen Belle, Pablo Berlanga, Nick J. Bird, Louis Chesler, Adam Durbin, Angelika Eggert, Martin Eilers, Sara M. Federico, Matthias Fischer, Susanne A. Gatz, Rani E. George, Sally George, Kelly C. Goldsmith, Juliet Gray, Andras Heczey, Meredith S. Irwin, Leona Knox, Holger N. Lode, Donna Ludwinski, Margaret E. Macy, Robbie G. Majzner, John M. Maris, Shakeel Modak, Jan J. Molenaar, Daniel A. Morgenstern, Yael P. Mossé, Cormac Owens, C. Patrick Reynolds, Claudia Rossig, Gudrun Schleiermacher, Liz Scott, Paul M. Sondel, Frank Speleman, Max van Noesel, Frank Westermann, Judith Wienke, Adam J. Wolpaw, Julie R. Park, Andrew D. J. Pearson   +44 more
wiley   +1 more source

Bispecific antibodies in follicular lymphoma

Haematologica
Bispecific antibodies, specifically anti-CD20 T-cell engaging constructs, are poised to alter the treatment paradigm of multiple B-cell malignancies, including follicular lymphoma. Two CD20xCD3 bispecific antibodies, mosunetuzumab and epcoritamab, are now approved in the United States for third-line or later treatment of follicular lymphoma.
Imran A. Nizamuddin, Nancy L. Bartlett
openaire   +3 more sources